Press Release
Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
01 May 2008 - Basingstoke, UK – 1st May 2008 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, welcomes the Court of Appeal’s decision that procedural fairness does require release of the fully executable version of the model on which NICE based its decision to restrict access on the NHS to drugs used for the treatment of Alzheimer’s disease, which includes Shire’s products Reminyl® and Reminyl® XL (galantamine hydrobromide).
The Court decided that NICE’s failure to disclose the fully executable version of the model put consultees, including Shire, at a significant disadvantage in challenging the reliability of the model. In that respect it limits their ability to make an intelligent response on something that is central to the appraisal process.
The Court has deferred its decision in relation to relief pending the parties having the opportunity to consider the judgment and agree a solution. This is now under active consideration. Shire looks forward to receiving the fully executable version and making representation on it.
Current NICE guidance denies access, on cost effective grounds, to drugs on the NHS to newly diagnosed patients with mild Alzheimer’s disease.
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
